Lilly Announces Agreement To Acquire ARMO BioSciences

$1.6 billion transaction will bolster Lilly's clinical portfolio with ARMO's lead immuno-oncology asset, pegilodecakin, which is being studied in multiple tumor types INDIANAPOLIS and REDWOOD CITY, Calif., May 10, 2018 -- (Healthcare Sales & Marketing N... Biopharmaceuticals, Oncology, Mergers & Acquisitions Eli Lilly, ARMO BioSciences, pegilodecakin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news